Announcement of Stock Split and Partial Revision to Articles Incorporation, Revisions to Dividend Forecast
Japan Lifeline Co., Ltd. ("Company") announced that the following resolutions were passed at the Board of Directors Meeting held on November 2, 2016 concerning a stock split and a partial revision to Articles of Incorporation, revisions to dividend forecast.
Stock split
Purpose of stock split
The purpose of this stock split is, by lowering the per-share investment price of Company stock, to create an easy investment environment, improve stock liquidity, and expand our investor base.
Overview of stock split
( i ) Stock split method
With November 30, 2016 (Wednesday) as the record date, Company will conduct a two-for-one split of common stock owned by shareholders registered in the final shareholder register as of said date.
(ii ) Increase in shares due to stock split
Total shares issued prior to stock split: 22,604,994 shares
Increase in shares due to stock split: 22,604,994 shares
Total shares issued following stock split: 45,209,988 shares Total number of authorized shares following stock split: 173,200,000 shares
(iii) Schedule for stock split
Publication of record date: November 16, 2016 (Wednesday) Record Date: November 30, 2016 (Wednesday)
Effective date: December 1, 2016 (Thursday)
Other information
The amount of stated capital will not be increased as a result of this stock split.
Partial revision to Articles of Incorporation
Reason for revision to Articles of Incorporation
In conjunction with this stock split, on December 1, 2016 the total number of authorized shares defined under Article 5 of our Articles of Incorporation will be revised upon the resolution of the Board of Directors Meeting held on November 2, 2016 in accordance with Article 184, Paragraph 2 of the Companies Act.
Detail of revision to Articles of Incorporation
(Underlined portion indicates change)
Current Articles of Incorporation
Revised Articles of Incorporation
(Total number of shares authorized to be issued) Article 5
The total number of shares authorized to be issued by Company shall be 86,600,000 shares.
(Total number of shares authorized to be issued) Article 5
The total number of shares authorized to be issued by Company shall be 173,200,000 shares.
Schedule for partial revision to Articles of Incorporation
Effective date of revision to Articles of Incorporation: December 1, 2016 (Thursday)
Revisions to dividend forecast
In light of this stock split, we are making the following changes to the dividend forecast for the fiscal year ending March 2017 disclosed in "Summary Report of Consolidated Financial Results for the Year Ended March 31, 2016 [Japan GAAP]" released on May 2, 2016.
Cash dividends per share
1Q End
2Q End
3Q End
Year-End
Total
Previous forecasts (Announced on May 2, 2016)
Yen
-
Yen
0.00
Yen
-
Yen
35.00
Yen
35.00
Revised forecasts
-
0.00
-
17.50
17.50
Actual results for the fiscal
year ending March 31, 2016
-
0.00
-
25.00
25.00
(Notes) Since the revision of the dividend forecast per share is accompanying with a stock split to increase the number of common stock outstanding, there is no substantive change from the year-end dividend forecast as 35 yen per share released on May 2, 2016.
JLL - Japan Lifeline Co. Ltd. published this content on 02 November 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 10 November 2016 16:14:12 UTC.
Original documenthttp://www.japanlifeline.com/pdf/announce/20161102_announcement_of_stock_split_and_partial.pdf
Public permalinkhttp://www.publicnow.com/view/DF3ACB62547BCE470C05E5227C63DF9475C2D81C
Japan Lifeline Co., Ltd. is a Japan-based company mainly engaged in the import, manufacture and sale of cardiac circulators and other medical devices. The Company is mainly engaged in the production of rhythm devices, electrophysiological (EP) and ablations, surgical products and intervention products. The rhythm devices include cardiac pacemakers, implantable cardioverter defibrillator (ICD), cardiac resynchronization therapy defibrillator (CRT-D) and other rhythm devices. The EP and ablations include EP catheters for cardiac arrhythmia examination, ablation catheters for arrhythmia treatment and other EP and ablations. The surgical products include prosthetic heart valves and annuloplasty rings for heart disease surgical treatment, vascular grafts, open stent grafts and stent grafts for aortic disease treatment, as well as other surgical products. The intervention products include balloon catheters, guide wires, penetration catheters and other intervention products.
JAPAN LIFELINE CO., LTD. 
